Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning

NCT ID: NCT00143832

Last Updated: 2007-03-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Poor inhibitory control has been proposed to be central to the cognitive deficits and symptomatology associated with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a highly heritable disorder with an increased incidence among the siblings of affected individuals. In the current proposal we investigate the expression of genetic susceptibility for ADHD in brain functioning. We will study cognitive functioning in patients with ADHD, their unaffected siblings and healthy matched controls. Our aims are 1) to determine whether increased familial risk for ADHD is associated with differential patterns of brain activation compared to normally developing children, during the performance of tasks designed to probe cognitive functions that are compromised in ADHD and 2) to determine whether differential patterns of activation are similar for boys with ADHD and their unaffected siblings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Poor inhibitory control has been proposed to be central to the cognitive deficits and symptomatology associated with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a highly heritable disorder with an increased incidence among the siblings of affected individuals. Although studies investigating candidate genes are underway, as yet it remains unclear via which mechanisms the presence of risk genes leads to symptomatology. There is evidence to suggest that individuals at increased genetic risk display some of the cognitive deficits associated with the disorder. In particular poor inhibitory control has been put forward as a potential marker for familial ADHD. Neuroimaging techniques now make it possible to investigate the neural substrate of cognitive deficits associated with psychiatric disorders. Magnetic resonance imaging (MRI) has been used to demonstrate that the neural substrate of cognitive brain function is affected in ADHD. Using a task that taxes inhibitory systems at varying levels of task demands, we demonstrated that increased susceptibility to interference in children with ADHD is paralleled by differences in brain activation, with these children displaying a relative lack of fronto-striatal activation. In a recent study, we demonstrated that the unaffected siblings of patients with ADHD show cortical volumetric deficits, similar to patients themselves. This suggests that individuals at increased risk for ADHD share some of the neural basis of cognitive deficits associated with this disorder. In the current proposal we set out to investigate the expression of genetic susceptibility for ADHD in brain functioning. We will study cognitive functioning in patients with ADHD, their unaffected siblings and healthy matched controls focusing on cognitive control. Our aims are 1) to determine whether increased familial risk for ADHD is associated with differential patterns of brain activation compared to normally developing children, during the performance of tasks designed to probe cognitive functions that are compromised in ADHD and 2) to determine whether differential patterns of activation are similar for boys with ADHD and their unaffected siblings. We intend to include 30 boys with ADHD, 30 of their brothers without ADHD, and 30 matched normal controls in 3 studies focusing on cognitive control and similar cognitive functions that are compromised in ADHD. We will include 10 boys in each group for each study. The proposed studies will utilize variations of a parametric go nogo paradigm previously developed. All subjects will be asked to participate in a functional MR scanning session lasting up to an hour. The whole visit will last a maximum of two hours. There are no known risks associated with MR scanning, therefore this procedure is considered completely safe. By participating in a simulation prior to the scan, we will also minimize anxiety for the subjects. Furthermore, the study will immediately be terminated if a subject becomes anxious, or otherwise indicates that he no longer wishes to participate. All subjects will be offered a gift certificate as a token of appreciation for their effort. In addition, they will be reimbursed for travel expenses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 8 - 20 years
* Male


* DSM-IV (APA, 1994) diagnosis of ADHD, according to DISC interview
* Scores in the clinical range on the Child Behavior Checklist (CBCL) and Teacher Rating Form(TRF)


* No DSM-IV (APA, 1994) diagnosis according to DISC interview
* No scores in the clinical range on the Child Behavior Checklist (CBCL) and Teacher Rating Form (TRF)


* No DSM-IV (APA, 1994) diagnosis, according to DISC interview
* No scores in the clinical range on the Child Behavior Checklist (CBCL) and Teacher Rating Form (TRF)

Exclusion Criteria

* IQ \< 70
* Illness of the cardiovascular, the endocrine, the pulmonal or the gastrointestinal system
* Presence of metal objects in or around the body (pacemaker, dental braces)
* History of or present neurological disorder
* For individuals over 12 years of age: legal incompetence, defined as the obvious inability to comprehend the information that is presented by the investigator and is outlined in the Information letter and on which the decision to participate in the study is to be based
Minimum Eligible Age

8 Years

Maximum Eligible Age

20 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Netherlands Organisation for Scientific Research

OTHER_GOV

Sponsor Role collaborator

UMC Utrecht

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sarah Durston, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

RMI of Neuroscience, UMC Utrecht

Herman van Engeland, M.D. Ph.D.

Role: STUDY_CHAIR

RMI of Neuroscience, UMC Utrecht

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept. of Child and Adolescent Psychiatry, UMC Utrecht

Utrecht, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sarah Durston, Ph.D.

Role: CONTACT

+31 30 250 8161

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Martijn Mulder, M.Sc.

Role: primary

+31 30 250 8161

Janna van Belle, M.Sc.

Role: backup

+31 30 250 3275

References

Explore related publications, articles, or registry entries linked to this study.

Durston S, Mulder M, Casey BJ, Ziermans T, van Engeland H. Activation in ventral prefrontal cortex is sensitive to genetic vulnerability for attention-deficit hyperactivity disorder. Biol Psychiatry. 2006 Nov 15;60(10):1062-70. doi: 10.1016/j.biopsych.2005.12.020. Epub 2006 May 19.

Reference Type RESULT
PMID: 16712804 (View on PubMed)

Durston S, Fossella JA, Mulder MJ, Casey BJ, Ziermans TB, Vessaz MN, VAN Engeland H. Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation. J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):61-67. doi: 10.1097/chi.0b013e31815a5f17.

Reference Type DERIVED
PMID: 18174826 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.niche-lab.nl

Lab homepage with info for subjects (in Dutch)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

METC 04/124

Identifier Type: -

Identifier Source: secondary_id

P03.0465C

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.